An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 27, 2010, Pages 2593-2605

  Sottani, Cristina ^a   Porro, Benedetta ^a   Comelli, Mario ^b   Imbriani, Marcello ^a,b   Minoia, Claudio ^a  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Biological monitoring; Environmental monitoring; HPLC MS MS; Programs for safely handling ADs

Indexed keywords

ADVERSE EFFECT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC DRUGS; BIOLOGICAL MONITORING; CHARACTERISATION; CLEANING PROCEDURES; CONTAMINATION LEVELS; ENVIRONMENTAL MONITORING; HPLC-MS/MS; LONG TERM; NEOPLASTIC DISEASE; OCCUPATIONAL EXPOSURE; POTENTIAL RISKS; PROGRAMS FOR SAFELY HANDLING ADS; STORAGE SYSTEMS; SURFACE CONTAMINATIONS; TANDEM MASS SPECTROMETRY; URINE SAMPLE;

ENVIRONMENTAL ENGINEERING; HEALTH; HEALTH CARE; HEALTH RISKS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALS; MASS SPECTROMETRY; SAFE HANDLING;

OCCUPATIONAL RISKS;

ANTINEOPLASTIC AGENT;

ARTICLE; BIOLOGICAL MONITORING; DRUG CONTAMINATION; DRUG EXPOSURE; HEALTH CARE PERSONNEL; HOSPITAL PHARMACY; HUMAN; ITALY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; SURFACE PROPERTY; URINALYSIS; WORKPLACE;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEALTH PERSONNEL; HUMANS; OCCUPATIONAL EXPOSURE; TANDEM MASS SPECTROMETRY;

EID: 77956933565     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.04.030     Document Type: Article

References (45)

1. Canadian Society of Hospital Pharmacists Guidelines for the handling of hazardous pharmaceuticals. Can. J. Hosp. Pharm. 1981, (July-August):37.
2. Clinical Oncological Society of Australia Guidelines and recommendations for safe handling of antineoplastic agents. Med. J. Aust. 1983, 1:426.
3. American Society of Hospital Pharmacists ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am. J. Hosp. Pharm. 1990, 47:1033.
4. Canadian Society of Hospital Pharmacists, Guidelines for the handling and disposal of hazardous pharmaceuticals (including cytotoxic drugs), Ottawa, Ontario, Canada, 1993.
5. Occupational Safety and Health Administration, OSHA Technical Manual, Hospital Investigations: Health Hazard, Section VI http://www.oshaslc.gov/SLTC/hazardousdrugs/index.html.
6. National Institute for Occupational Safety and Health (NIOSH), Preventing occupational exposure to antineoplastic and other hazardous drugs in healthcare settings, NIOSH Publication 165, 2004. http://www.cdc.gov/niosh/docs/2004-165.
7. Provvedimento 5 agosto 1999, Documento di linee-guida per la sicurezza e la salute dei lavoratori esposti a chemioterapici antiblastici in ambiente sanitario, G.U. 236, 7.10.1999 (Italian Guidelines).
8. Valanis B.G., Vollmer W.M., Labuhn K.T., Glass A.G. Am. J. Hosp. Pharm. 1993, 50:455.
9. Krstey S., Perunicić B., Vidacović A. Med. Lav. 2003, 94:432.
10. Stücker I., Mandereau L., Hémon D. Scand. J. Work Environ. Health 1993, 19:148.
11. Valanis B., Vollmer W.M., Steele P. J. Occup. Environ. Med. 1999, 41:632.
12. Fransman W., Peelen S., Hilhorst S., Roeleveld N., Heederik D., Kromhouts H. Ann. Occup. Hyg. 2007, 51:231.
13. Rombaldi F., Cassini C., Salvador M., Saffi J., Erdtmann B. Mutagenesis 2009, 24:143.
14. Cavallo D., Ursini C.L., Perniconi B., Di Francesco A., Giglio M., Rubino F.M., Marinaccio A., Iavicoli S. Mutat. Res. 2005, 587:45.
15. IARC monographs on the evaluation of the carcinogenic risk to humans, Suppl 7, Overall evaluation of carcinogenity: an updating of IARC monographs volumes 1-42, International Agency for Research on Cancer, Lyon, 7, 1987.
16. IARC monographs on the evaluation of the carcinogenic risk to humans, vol. 50, Pharmaceuticals drugs, International Agency for Research on Cancer, Lyon, 50, 1990.
17. Connor T.H. Ann. N. Y. Acad. Sci. 2006, 1076:615.
18. Turci R., Minoia C. Ann. N. Y. Acad. Sci. 2006, 1076:649.
19. Acampora A., Castiglia L., Miraglia N., Pieri M., Soave C., Liotti F., Cannolo N. Ann. Occup. Hyg. 2005, 49:611.
20. Roberts S., Khammo N., McDonnell G., Sewell G.J. J. Oncol. Pharm. Pract. 2006, 12:95.
21. Hedmer M., Tinnerberg H., Axmon A., Jönsson B.A.G. Int. Arch. Occup. Environ. Health 2008, 81:899.
22. Hardy R.W., Erlichman C., Soldin S.J. Ther. Drug Monit. 1984, 6:313.
23. Burton L.C., James C.A. J. Chromatogr. 1988, 431:450.
24. Ensslin A.S., Stoll Y., Perthan A., Pfaller A., Rommelt H., Fruhmann G. Occup. Environ. Med. 1994, 51:229.
25. Evelo C.T.A., Bos R.P., Peter J.G.P., Henderson P.Th. Int. Arch. Occup. Environ. Health 1986, 58:151.
26. Sessink P.J., Scholtes M.M., Anzion R.B., Bos R.P. J. Chromatogr. 1993, 616(2):333.
27. Sessink P.J., Vaes W.H., van den Broek P.H., Noordhoek J., Bos R.P. J. Chromatogr. B Biomed. Appl. 1995, 673(2):205.
28. Momerency G., Van Cauwenberghe K., Slee P.H., Van Oosterom A.T., De Bruijn E.A. Biol. Mass Spectrom. 1994, 23(3):149.
29. Sannolo N., Miraglia N., Biglietto M., Acampora A., Malorni A. J. Mass Spectrom. 1999, 34:845.
30. Stokvis E., Rosing H., Beijnen J.H. Mass Spectrom. Rev. 2005, 24:887.
31. Barbieri A., Sabatini L., Indiveri P., Bonfiglioli R., Lodi V., Violante F.S. Rapid Commun. Mass Spectrom. 2006, 20:1889.
32. De Miranda Silva C., Dumêt Fernandes B.J., Marques Pereira M.P., Da Silva L.M., Donadi E.A., Do Carmo Silva Matthes A., Moreira De Andrade J., Lanchote V.L. Chirality 2009, 21:383.
33. Ekhart C., Gebretensae A., Rosing H., Rodenhuis S., Beijnen J.H., Huitema A.D.R. J. Chromatogr. B 2007, 854:345.
34. Sottani C., Turci R., Perbellini L., Minoia C. Rapid Commun. Mass Spectrom. 1998, 12:1063.
35. Sottani C., Tranfo G., Faranda P., Minoia C. Rapid Commun. Mass Spectrom. 2005, 19:2794.
36. Sottani C., Turci R., Schierl R., Gaggeri R., Barbieri A., Violante F.S., Minoia C. Rapid Commun. Mass Spectrom. 2007, 21:1289.
37. Silvertand L.H.H., Vazvaei F., Weigl P., Rosing H., Hillebrand M.J.X., van Maanen M.J., Beijnen J.H. Rapid Commun. Mass Spectrom. 2005, 19:3673.
38. Sabatini L., Barbieri A., Tosi M., Violante F.S. J. Mass Spectrom. 2005, 40:669.
39. Hedmer M., Jönsson B.A.G., Nygren O. J. Environ. Monit. 2004, 6:979.
40. Ziegler E., Mason H.J., Baxter P.J. Occup. Environ. Med. 2002, 59:608.
41. Quantifying Uncertainty in Analytical Measurement, EURACHEM/CITAC Guide, 2nd edn, Final Draft, EURACHEM/CITAC: Teddington, UK, 2000, Available: http://www.eurachem.ul.pt/.
42. Guidance for industry: bioanalytical method validation, FDA, US Department of Health and Human Services, 2001, Available: http://www.fda.gov/cder/guidance/4252fnl.pdf.
43. Qualitative risk characterization and management of occupational hazards (control banding [CB]): a literature review and critical analysis, Available: http://www.cdc.gov/niosh/review/public/138.
44. Sottani C., Tranfo G., Bettinelli M., Faranda P., Spagnoli M., Minoia C. Rapid Commun. Mass Spectrom. 2004, 18:2426.
45. Jakubowski M., Trzcinka-Ochocka M. J. Occup. Health 2005, 47(22). (Review). 10.1539/joh.47.22.